Paclitaxel is incorporated by mesenchymal stromal cells and released in exosomes that inhibit in vitro tumor growth: A new approach for drug delivery

Pascucci, Luisa; Coccè, Valentina; Bonomi, Andrea; Ami, Diletta; Ceccarelli, Piero; Ciusani, Emilio; Viganò, Lucia; Locatelli, Alberta; Sisto, Francesca; Doglia, Silvia Maria; Parati, Eugenio; Bernardo, Maria Ester; Muraca, Maurizio; Alessandri, Giulio; Bondiolotti, Gianpietro; Pessina, Augusto

doi:10.1016/j.jconrel.2014.07.042

Cited by 703 publications

(502 citation statements)

References 52 publications

Supporting

Mentioning

493

Contrasting

Unclassified

Order By: Relevance

“…93 In 2014, Pascucci et al showed that Mesenchymal Stem Cells (MSC) could incorporate and deliver Paclitaxel to recipient cells through exosomes with increased anti-tumor effects. 94 This study suggests that MSC-derived exosomes could be a new strategy for drug delivery in cancer treatment. Exosomes have also been used as cargos of paclitaxel to increase the effectiveness of the treatment in prostate cancer cells.…”

Section: Exosomes As Drug Delivery Cargosmentioning

confidence: 83%

Exosomes in cancer theranostic: Diamonds in the rough

Cordonnier

Chanteloup

Isambert

et al. 2017

Cell Adhesion & Migration

View full text Add to dashboard Cite

During the last 10 years, exosomes, which are small vesicles of 50-200 nm diameter of endosomal origin, have aroused a great interest in the scientific and clinical community for their roles in intercellular communication in almost all physiological and pathological processes. Most cells can potentially release these nanovesicles that share with the parent cell a similar lipid bilayer with transmembrane proteins and a panel of enclosed soluble proteins such as heat shock proteins and genetic material, thus acting as potential nanoshuttles of biomarkers. Exosomes surface proteins allow their targeting and capture by recipient cells, while the exosomes' content can modify the physiological state of recipient cells. Tumor derived exosomes by interacting with other cells of the tumor microenvironment modulate tumor progression, angiogenic switch, metastasis, and immune escape. Targeting tumor-derived exosomes might be an interesting approach in cancer therapy. Furthermore, because a key issue to improve cancer patients' outcome relies on earlier cancer diagnosis (metastases, as opposed to the primary tumor, are responsible for most cancer deaths) exosomes have been put forward as promising biomarker candidates for cancer diagnosis and prognosis. This review summarizes the roles of exosomes in cancer and clinical interest, focusing on the importance of exosomal heat shock proteins (HSP). The challenges of clinical translation of HSPexosomes as therapeutic targets and biomarkers for early cancer detection are also discussed.

show abstract

Section: Exosomes As Drug Delivery Cargosmentioning

confidence: 83%

Exosomes in cancer theranostic: Diamonds in the rough

Cordonnier

Chanteloup

Isambert

et al. 2017

Cell Adhesion & Migration

View full text Add to dashboard Cite

show abstract

“…MSCs) with free paclitaxel, has also been evaluated. The paclitaxel-loaded EVs that were secreted by the MSCs induced an anti-proliferative effect on in vitro cultured adenocarcinoma cells [152].…”

Section: Loading Evs With a Therapeutic Cargomentioning

confidence: 99%

“…Indeed, when comparing both loading strategies for paclitaxel, the post-formation method yields ~21 mg/g EV [175] and ~7.3 mg/g EV [131] compared to ~2 µg/g EV [152] for the pre-formation method. Overall, loading hydrophobic small molecules in EVs is more straightforward and efficient.…”

Section: Loading Evs With a Therapeutic Cargomentioning

confidence: 99%

Therapeutic and diagnostic applications of extracellular vesicles

Stremersch

Smedt

Raemdonck

2016

Journal of Controlled Release

151

View full text Add to dashboard Cite

During the past two decades, extracellular vesicles (EVs) have been identified as important mediators of intercellular communication, enabling the functional transfer of bioactive molecules from one cell to another. Consequently, it is becoming increasingly clear that these vesicles are involved in many (patho)physiological processes, providing opportunities for therapeutic applications. Moreover, it is known that the molecular composition of EVs reflects the physiological status of the producing cell and tissue, rationalizing their exploitation as biomarkers in various diseases. In this review the composition, biogenesis and diversity of EVs is discussed in a therapeutic and diagnostic context. We describe emerging therapeutic applications, including the use of EVs as drug delivery vehicles and as cell-free vaccines, and reflect on future challenges for clinical translation. Finally, we discuss the use of EVs as a biomarker source and highlight recent studies and clinical successes.

show abstract

“…Indeed, Osterman et al showed that exosome-bound curcumin is readily taken up by cultured PDAC cells and is effective in inducing cytotoxicity [82]. Moreover, Pascucci et al demonstrated that mesenchymal stromal cell-derived exosomes can effectively deliver active drugs, such as paclitaxel, to inhibit tumor growth [83]. Interestingly, studies have shown that survivin resides in exosomes [84,85].…”

Section: Exosomes As Drug Delivery Vehiclesmentioning

confidence: 99%

Exosomes: Navigating a New Route in Pancreatic Cancer

Zhang¹,

Wang²,

Xu³

et al. 2017

J Biomol Res Ther

View full text Add to dashboard Cite

Pancreatic cancer is a fatal disease, and even with an increased commitment to pancreatic cancer research, the 5-year survival rate remains at approximately 6%. However, in the last decade, there has been a rising interest in the role of small extracellular vesicles called exosomes in the cancer field. Accumulating evidence shows that exosomes participate in early processes of tumorigenesis, tumor progression, and metastasis by mediating communication between cells or between cells and their surrounding microenvironment. In pancreatic cancer, exosomes play key roles in building pre-metastatic niches in the liver, inducing immune evasion, changing metabolism, mediating crosstalk between tumor and stromal cells, and causing low chemosensitivity. Although research exploring the roles of exosomes in pancreatic cancer is still in its infancy, the studies presented in this review highlight their potential value in developing novel tools, such as lipid biomarkers, treatment targets, and efficient drug delivery devices, for cancer diagnosis and therapy.

show abstract

Paclitaxel is incorporated by mesenchymal stromal cells and released in exosomes that inhibit in vitro tumor growth: A new approach for drug delivery

Cited by 703 publications

References 52 publications

Exosomes in cancer theranostic: Diamonds in the rough

Exosomes in cancer theranostic: Diamonds in the rough

Therapeutic and diagnostic applications of extracellular vesicles

Exosomes: Navigating a New Route in Pancreatic Cancer

Contact Info

Product

Resources

About